Prosecution Insights
Last updated: November 20, 2026
Application No. 18/717,142

Polypodal Serotonergic Compounds and Prodrugs of Serotonin Receptors Agonists and Antagonists

Non-Final OA §112
Filed
Jun 06, 2024
Priority
Dec 24, 2021 — provisional 63/293,730 +4 more
Examiner
WILLIS, DOUGLAS M
Art Unit
1624
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Kuleon LLC
OA Round
1 (Non-Final)
82%
Grant Probability
Favorable
1-2
OA Rounds
0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 82% — above average
82%
Career Allowance Rate
1504 granted / 1825 resolved
+22.4% vs TC avg
Strong +20% interview lift
Without
With
+19.8%
Interview Lift
resolved cases with interview
Fast prosecutor
1y 10m
Avg Prosecution
68 currently pending
Career history
1875
Total Applications
across all art units

Statute-Specific Performance

§101
0.9%
-39.1% vs TC avg
§103
8.9%
-31.1% vs TC avg
§102
17.8%
-22.2% vs TC avg
§112
52.9%
+12.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1825 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The inventor or joint inventor should note that the instant invention, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Status of the Claims Claims 1-14, 19, 23, 24, 27, 28 and 31 are pending in the instant invention. According to the Amendments to the Claims, filed August 20, 2026, claim 1 was amended and claims 15-18, 20-22, 25, 26, 29 and 30 were cancelled. Status of Priority This invention is a 35 U.S.C. § 371 National Stage Filing of International Application No. PCT/US2022/053910, filed December 23, 2022, which claims priority under 35 U.S.C. § 119(e) to: US Provisional Application Nos.: a) 63/338,994, filed May 6, 2022; b) 63/299,817, filed January 14, 2022; and c) 63/293,730, filed December 24, 2021. Restrictions / Election of Species PNG media_image1.png 245 616 media_image1.png Greyscale The inventor’s or joint inventor’s provisional election of the following, with traverse, in the reply filed on August 20, 2026, is acknowledged: a) Group I - claims 1-14, 19, 23, 24, 27, 28 and 31; and b) substituted dimer of Formula IG - p. 163, Table 1, example 479, shown to the right below, and hereafter referred to as 1,5-bis[3-[2-(dimethyl-amino)ethyl]-1H-indol-4-yl]pentanedioic acid ester, where X = -CH3; Y = -CH3; R3 = -H; R3’ = -H; W2 = -CH2-; R2 = -H; W1 = -NR1-, wherein R1 = -H; Z5 = CR5, wherein R5 = -H; Z6 = CR6, wherein R6 = -H; Z7 = CR7, wherein R7 = -H; L1 = -O-; L2= -CR10R10-, wherein each R10 PNG media_image2.png 205 527 media_image2.png Greyscale = -H; n = 1; L3= -CR10R10-, wherein each R10 = -H; p = 1; L4= -CR10R10-, wherein each R10 = -H; q = 1; L5 = -O-; Z7a = CR7, wherein R7 = -H; Z6a = CR6, wherein R6 = -H; Z5a = CR5, wherein R5 = -H; W1a = -NR1-, wherein R1 = -H; R2a = -H; W2a = -CH2-; R3a = -H; R3a’ = -H; X1 = -CH3; and Y1 = -CH3. Claims 1-9, 19, 23, 24, 27, 28 and 31 read on the elected species. Affirmation of this election must be made by the inventor or joint inventor in replying to this Office action. Similarly, the inventor or joint inventor should further note that since supposed errors in the restriction requirement were not distinctly and specifically pointed out, the election has been treated as an election, without traverse. See MPEP § 818.03(a). Likewise, the inventor or joint inventor should further note that the requirement is still deemed proper and is therefore made FINAL. Moreover, the inventor or joint inventor should further note that the elected species, shown to the right above, was found to be free of the prior art. Thus, the examiner has expanded the forthcoming prosecution to include all claims relevant to the genus of Group I, for a first Office action and prosecution on the merits. Thus, a first Office action and prosecution on the merits of claims 1-14, 19, 23, 24, 27, 28 and 31 is contained within. Specification Objection - Disclosure The following guidelines illustrate the preferred layout for the specification of a utility application. These guidelines are suggested for the inventor’s or joint inventor’s use. Arrangement of the Specification As provided in 37 CFR 1.77(b), the specification of a utility invention should include the following sections in order. Each of the lettered items should appear in upper case, without underlining or bold type, as a section heading. If no text follows the section heading, the phrase Not Applicable should follow the section heading: (a) TITLE OF THE INVENTION. (b) CROSS-REFERENCE TO RELATED APPLICATIONS. (c) STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT. (d) THE NAMES OF THE PARTIES TO A JOINT RESEARCH AGREEMENT. (e) INCORPORATION-BY-REFERENCE OF MATERIAL SUBMITTED ON A COMPACT DISC. (f) BACKGROUND OF THE INVENTION. (1) Field of the Invention. (2) Description of Related Art (including information disclosed under 37 CFR 1.97 and 1.98). (g) BRIEF SUMMARY OF THE INVENTION. (h) BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWING(S). (i) DETAILED DESCRIPTION OF THE INVENTION. (j) CLAIM OR CLAIMS (commencing on a separate sheet). (k) ABSTRACT OF THE DISCLOSURE (commencing on a separate sheet). (l) SEQUENCE LISTING (See MPEP § 2424 and 37 CFR 1.821-1.825). The inventor or joint inventor is advised to format the specification according to 37 CFR 1.77(b) above and 37 CFR 1.77(c). Revisions should particularly include and/or address: a) section headings (b-i), where applicable; and b) bold-type, underline, and/or upper case formatting. Appropriate correction may be required. Specification Objection - Abstract The inventor or joint inventor is reminded of the proper content of an abstract of the disclosure. With regard particularly to chemical patents, for compounds or compositions, the general nature of the compound or composition should be given as well as the use thereof, e.g., The compounds are of the class of alkyl benzene sulfonyl ureas, useful as oral anti-diabetics. Exemplification of a species could be illustrative of members of the class. For processes, the reactions, reagents and process conditions should be stated, generally illustrated by a single example, unless variations are necessary. See MPEP § 608.01(b), Section B. The abstract of the disclosure is objected to because it fails to exemplify any members or formulae illustrative of its class. Correction is required. See MPEP § 608.01(b). The examiner suggests incorporating the structure of Formula IG into the abstract, to overcome this objection. Claim Objections Claim 1 is objected to because of the following informalities: for clarity, precision and to avoid issues under 35 U.S.C. § 112(a) and/or 35 U.S.C. § 112(b), the existing recitation should be replaced with the following recitation: A compound of Formula IG: PNG media_image3.png 306 770 media_image3.png Greyscale Formula IG or a pharmaceutically acceptable salt or stereoisomer thereof, wherein: X is C1-C8 alkyl or C2-C8 alkenyl, wherein the C1-C8 alkyl or C2-C8 alkenyl is optionally substituted with one or more substituents independently selected from the group consisting of D, halo, OH, O(alkyl), S(O)2NH(alkyl), S(O)2NH(aryl), aryl, and heteroaryl; Y is C1-C8 alkyl or C2-C8 alkenyl, wherein the C1-C8 alkyl or C2-C8 alkenyl is optionally substituted with one or more substituents independently selected from the group consisting of D, halo, OH, O(alkyl), S(O)2NH(alkyl), S(O)2NH(aryl), aryl, and heteroaryl; or X and Y, taken together with the nitrogen atom to which they are attached, form a 3- to 7-membered heterocyclyl, wherein the 3- to 7-membered heterocyclyl optionally contains 1 or 2 additional ring heteromoieties independently selected from the group consisting of -NR9-, -O-, -S-, -S(O)-, and -S(O)2-; or R3’ is H, D, halo, C1-C8 alkyl, C2-C8 alkenyl, NR9R9, OC1-C8 alkyl, or SR9, wherein the C1-C8 alkyl or C2-C8 alkenyl is optionally substituted with one or more substituents independently selected from the group consisting of D, halo, OH, O(alkyl), S(O)2NH(alkyl), S(O)2NH(aryl), aryl, and heteroaryl; R3 is H, D, halo, C1-C8 alkyl, C2-C8 alkenyl, NR9R9, OC1-C8 alkyl, or SR9, wherein the C1-C8 alkyl or C2-C8 alkenyl is optionally substituted with one or more substituents independently selected from the group consisting of D, halo, OH, O(alkyl), S(O)2NH(alkyl), S(O)2NH(aryl), aryl, and heteroaryl; W2 is -CH2-, -CHD-, -CD2-, -CH2CH2-, or -CD2CD2-; R2 is H, D, halo, C1-C8 alkyl, C2-C8 alkenyl, NR9R9, OC1-C8 alkyl, or SR9, wherein the C1-C8 alkyl or C2-C8 alkenyl is optionally substituted with one or more substituents independently selected from the group consisting of D, halo, OH, O(alkyl), S(O)2NH(alkyl), S(O)2NH(aryl), aryl, and heteroaryl; W1 is -NR1-, -O-, -S-, -S(O)-, -Se-, -Se(O)-, or -Se(O)2-; Z5 is CR5 or N; Z6 is CR6 or N; Z7 is CR7 or N; L1 is -O-; L2 is -CR10R10-, -O-, or -S-; n is 0, 1, 2, 3, or 4; each L3 is independently -CR10R10-, -CR10=CR10-, -NR10-, -O-, -S-, cycloalkylene, heterocyclylene, arylene, or heteroarylene; wherein each cycloalkylene and heterocyclylene is optionally and independently substituted with one or more substituents independently selected from the group consisting of D, halo, alkyl, OH, aryl, and heteroaryl; and wherein each arylene and heteroarylene is optionally and independently substituted with one or more substituents independently selected from the group consisting of D, halo, alkyl, OH, aryl, and heteroaryl; p is 0, 1, 2, 3, or 4; L4 is -CR10R10-, -O-, or -S-; q is 0, 1, 2, 3, or 4; L5 is -O-; Z5a is CR5 or N; Z6a is CR6 or N; Z7a is CR7 or N; W1a is -NR1-, -O-, -S-, -S(O)-, -Se-, -Se(O)-, or -Se(O)2-; R2a is H, D, halo, C1-C8 alkyl, C2-C8 alkenyl, NR9R9, OC1-C8 alkyl, or SR9, wherein the C1-C8 alkyl or C2-C8 alkenyl is optionally substituted with one or more substituents independently selected from the group consisting of D, halo, OH, O(alkyl), S(O)2NH(alkyl), S(O)2NH(aryl), aryl, and heteroaryl; W2a is -CH2-, -CHD-, -CD2-, -CH2CH2-, or -CD2CD2-; R3a is H, D, halo, C1-C8 alkyl, C2-C8 alkenyl, NR9R9, OC1-C8 alkyl, or SR9, wherein the C1-C8 alkyl or C2-C8 alkenyl is optionally substituted with one or more substituents independently selected from the group consisting of D, halo, OH, O(alkyl), S(O)2NH(alkyl), S(O)2NH(aryl), aryl, and heteroaryl; R3a’ is H, D, halo, C1-C8 alkyl, C2-C8 alkenyl, NR9R9, OC1-C8 alkyl, or SR9, wherein the C1-C8 alkyl or C2-C8 alkenyl is optionally substituted with one or more substituents independently selected from the group consisting of D, halo, OH, O(alkyl), S(O)2NH(alkyl), S(O)2NH(aryl), aryl, and heteroaryl; X1 is C1-C8 alkyl or C2-C8 alkenyl, wherein the C1-C8 alkyl or C2-C8 alkenyl is optionally substituted with one or more substituents independently selected from the group consisting of D, halo, OH, O(alkyl), S(O)2NH(alkyl), S(O)2NH(aryl), aryl, and heteroaryl; Y1 is C1-C8 alkyl or C2-C8 alkenyl, wherein the C1-C8 alkyl or C2-C8 alkenyl is optionally substituted with one or more substituents independently selected from the group consisting of D, halo, OH, O(alkyl), S(O)2NH(alkyl), S(O)2NH(aryl), aryl, and heteroaryl; or X1 and Y1, taken together with the nitrogen atom to which they are attached, form a 3- to 7-membered heterocyclyl, wherein the 3- to 7-membered heterocyclyl optionally contains 1 or 2 additional ring heteromoieties independently selected from the group consisting of -NR9-, -O-, -S-, -S(O)-, and -S(O)2-; each R1 is independently H, D, C1-C8 alkyl, C2-C8 alkenyl, C(O)R8, C(O)NR9R9, C(O)OR8, P(O)(OR9)(OR9), S(O)R8, or S(O)2R8, wherein each C1-C8 alkyl and C2-C8 alkenyl is optionally and independently substituted with one or more substituents independently selected from the group consisting of D, halo, OH, O(alkyl), S(O)2NH(alkyl), S(O)2NH(aryl), aryl, and heteroaryl; each R5 is independently H, D, halo, C1-C8 alkyl, C2-C8 alkenyl, NR9R9, OH, OC1-C8 alkyl, OC(O)R8, OC(O)OR8, OP(O)(OR9)(OR9), OS(O)2R8, or SR9, wherein each C1-C8 alkyl and C2-C8 alkenyl is optionally and independently substituted with one or more substituents independently selected from the group consisting of D, halo, OH, O(alkyl), S(O)2NH(alkyl), S(O)2NH(aryl), aryl, and heteroaryl; each R6 is independently H, D, halo, C1-C8 alkyl, C2-C8 alkenyl, NR9R9, OC1-C8 alkyl, or SR9, wherein each C1-C8 alkyl and C2-C8 alkenyl is optionally and independently substituted with one or more substituents independently selected from the group consisting of D, halo, OH, O(alkyl), S(O)2NH(alkyl), S(O)2NH(aryl), aryl, and heteroaryl; each R7 is independently H, D, halo, C1-C8 alkyl, C2-C8 alkenyl, NR9R9, OC1-C8 alkyl, or SR9, wherein each C1-C8 alkyl and C2-C8 alkenyl is optionally and independently substituted with one or more substituents independently selected from the group consisting of D, halo, OH, O(alkyl), S(O)2NH(alkyl), S(O)2NH(aryl), aryl, and heteroaryl; each R8 is independently C1-C8 alkyl, C2-C8 alkenyl, or aryl; wherein each C1-C8 alkyl and C2-C8 alkenyl is optionally and independently substituted with one or more substituents independently selected from the group consisting of D, halo, OH, O(alkyl), S(O)2NH(alkyl), S(O)2NH(aryl), aryl, and heteroaryl; and wherein each aryl is optionally and independently substituted with one or more substituents independently selected from the group consisting of D, halo, alkyl, OH, aryl, and heteroaryl; each R9 is independently H, D, C1-C8 alkyl, C2-C8 alkenyl, or aryl; wherein each C1-C8 alkyl and C2-C8 alkenyl is optionally and independently substituted with one or more substituents independently selected from the group consisting of D, halo, OH, O(alkyl), S(O)2NH(alkyl), S(O)2NH(aryl), aryl, and heteroaryl; and wherein each aryl is optionally and independently substituted with one or more substituents independently selected from the group consisting of D, halo, alkyl, OH, aryl, and heteroaryl; and each R10 is independently H, D, C1-C8 alkyl, or C2-C8 alkenyl, wherein each C1-C8 alkyl and C2-C8 alkenyl is optionally and independently substituted with one or more substituents independently selected from the group consisting of D, halo, OH, O(alkyl), S(O)2NH(alkyl), S(O)2NH(aryl), aryl, and heteroaryl. Appropriate correction is required. See MPEP § 2173.02. Claim 2 is objected to because of the following informalities: for clarity and precision, the existing recitation should be replaced with the following recitation: The compound according to claim 1, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein: X is C1-C8 alkyl; and X1 is C1-C8 alkyl. Appropriate correction is required. See MPEP § 2173.02. Claim 3 is objected to because of the following informalities: for clarity and precision, the existing recitation should be replaced with the following recitation: The compound according to claim 2, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein: Y is C1-C8 alkyl; and Y1 is C1-C8 alkyl. Appropriate correction is required. See MPEP § 2173.02. Claim 4 is objected to because of the following informalities: for clarity and precision, the existing recitation should be replaced with the following recitation: The compound according to claim 1, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein: W2 is -CH2-, -CHD-, or -CD2-; and W2a is -CH2-, -CHD-, or -CD2-. Appropriate correction is required. See MPEP § 2173.02. Claim 5 is objected to because of the following informalities: for clarity and precision, the existing recitation should be replaced with the following recitation: The compound according to claim 1, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein: R2 is H; and R2a is H. Appropriate correction is required. See MPEP § 2173.02. Claim 6 is objected to because of the following informalities: for clarity and precision, the existing recitation should be replaced with the following recitation: The compound according to claim 1, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein: R3’ is H, D, or CH3; R3 is H, D, or CH3; R3a is H, D, or CH3; and R3a’ is H, D, or CH3. Appropriate correction is required. See MPEP § 2173.02. Claim 7 is objected to because of the following informalities: for clarity and precision, the existing recitation should be replaced with the following recitation: The compound according to claim 1, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein: R3’ is H or D; R3 is H or D; R3a is H or D; and R3a’ is H or D. Appropriate correction is required. See MPEP § 2173.02. Claim 8 is objected to because of the following informalities: for clarity and precision, the existing recitation should be replaced with the following recitation: The compound according to claim 1, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein: Z5 is CR5; and Z5a is CR5. Appropriate correction is required. See MPEP § 2173.02. Claim 9 is objected to because of the following informalities: for clarity and precision, the existing recitation should be replaced with the following recitation: The compound according to claim 8, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein each R5 is independently H or halo. Appropriate correction is required. See MPEP § 2173.02. Claim 10 is objected to because of the following informalities: for clarity and precision, the existing recitation should be replaced with the following recitation: The compound according to claim 1, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein at least one of Z6, Z6a, Z7, and Z7a is N. Appropriate correction is required. See MPEP § 2173.02. Claim 11 is objected to because of the following informalities: for clarity and precision, the existing recitation should be replaced with the following recitation: The compound according to claim 10, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein: Z6 is N; and Z6a is N. Appropriate correction is required. See MPEP § 2173.02. Claim 12 is objected to because of the following informalities: for clarity and precision, the existing recitation should be replaced with the following recitation: The compound according to claim 10, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein: Z7 is N; and Z7a is N. Appropriate correction is required. See MPEP § 2173.02. Claim 13 is objected to because of the following informalities: for clarity and precision, the existing recitation should be replaced with the following recitation: The compound according to claim 10, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein: Z6 is CR6; and Z6a is CR6. Appropriate correction is required. See MPEP § 2173.02. Claim 14 is objected to because of the following informalities: for clarity and precision, the existing recitation should be replaced with the following recitation: The compound according to claim 13, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein each R6 is independently H, halo, or OC1-C4 alkyl. Appropriate correction is required. See MPEP § 2173.02. Claim 19 is objected to because of the following informalities: for clarity and precision, the existing recitation should be replaced with the following recitation: The compound according to claim 1, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein: W1 is -NR1-; and W1a is -NR1-. Appropriate correction is required. See MPEP § 2173.02. Claim 23 is objected to because of the following informalities: for clarity and precision, the existing recitation should be replaced with the following recitation: The compound according to claim 19, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein: L1 is -O-; and L5 is -O-. Appropriate correction is required. See MPEP § 2173.02. Claim 24 is objected to because of the following informalities: for clarity and precision, the existing recitation should be replaced with the following recitation: The compound according to claim 23, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein: L2 is -CR10R10- or -O-; and L4 is -CR10R10- or -O-. Appropriate correction is required. See MPEP § 2173.02. Claim 27 is objected to because of the following informalities: for clarity and precision, the existing recitation should be replaced with the following recitation: The compound according to claim 24, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein: n is 1,2, 3, or 4; and q is 1,2, 3, or 4. Appropriate correction is required. See MPEP § 2173.02. Claim 28 is objected to because of the following informalities: for clarity and precision, the existing recitation should be replaced with the following recitation: The compound according to claim 1, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein each L3 is independently -CR10R10-, -O- or -S-. Appropriate correction is required. See MPEP § 2173.02. Claim 31 is objected to because of the following informalities: for clarity and precision, the existing recitation should be replaced with the following recitation: The compound according to claim 24, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein p is 1,2, 3, or 4. Appropriate correction is required. See MPEP § 2173.02. Claim Rejections - 35 U.S.C. § 112(a) The following is a quotation of the first paragraph of 35 U.S.C. § 112: (a) IN GENERAL. The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. Substituted dimers of the Formula IG Claims 1-14, 19, 23, 24, 27, 28 and 31 are rejected under 35 U.S.C. § 112(a) because the specification, while being enabling for substituted dimers of the Formula IG, wherein the substituted dimers of the Formula IG are as presented herein in the section above entitled Claim Objections, does not reasonably provide enablement for substituted dimers of the Formula IG, wherein the substituted dimers of the Formula IG are not as presented herein in the section above entitled Claim Objections. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention commensurate in scope with these claims. Substituted dimers of the Formula IG, wherein the substituted dimers of the Formula IG are not as presented herein in the section above entitled Claim Objections, as recited in claim 1, have not been adequately enabled in the specification to allow any person having ordinary skill in the art, at the time this invention was made, to make and/or use substituted dimers of the Formula IG, wherein the substituted dimers of the Formula IG are not as presented herein in the section above entitled Claim Objections. There are many factors to be considered when determining whether there is sufficient evidence to support a determination that a disclosure does not satisfy the enablement requirement and whether any necessary experimentation is undue. These factors include, but are not limited to: (a) breadth of the claims; (b) nature of the invention; (c) state of the prior art; (d) level of one of ordinary skill in the art; (e) level of predictability in the art; (f) amount of direction provided by the inventor or joint inventor; (g) existence of working examples; and (h) quantity of experimentation needed to make or use the invention based on the content of the disclosure. {See Ex parte Forman 230 USPQ 546 (Bd. Pat. App. & Inter. 1986); and In re Wands, 8 USPQ2d 1400 (Fed. Cir. 1988)}. The above factors, regarding the instant invention, are summarized as follows: PNG media_image4.png 219 553 media_image4.png Greyscale (a) Breadth of the claims - the breadth of the claims includes substituted dimers of the Formula IG, shown to the right; (b) Nature of the invention - the nature of the invention is evaluation of substituted dimers of the Formula IG, shown to the right, and the pharmacokinetic behavior of these substances as polypodal serotonergics; (c) State of the prior art - Nature Reviews: Drug Discovery offers a snapshot of the state of the drug development art. Herein, drug development is stated to follow the widely accepted Ehrlich model which includes: (1) development of a broad synthetic organic chemistry program; (2) subsequent testing of compounds in an appropriate laboratory model for the disease to be treated; and (3) screening of compounds with low toxicity in prospective clinical trials (Jordan, V. C. Nature Reviews: Drug Discovery, 2, 2003, 205). Moreover, WO 23/122320 provides a synthesis of the instantly recited substituted dimers of the Formula IG {Gilles, D. WO 23/122320, 2023}; (d) Level of one of ordinary skill in the art - the artisans synthesizing the inventor’s or joint inventor’s substituted dimers of the Formula IG, wherein the substituted dimers of the Formula IG are not as presented herein in the section above entitled Claim Objections, would be a collaborative team of synthetic chemists and/or health practitioners, possessing commensurate degree level and/or skill in the art, as well as several years of professional experience; (e) Level of predictability in the art - Synthetic organic chemistry is quite unpredictable (See In re Marzocchi and Horton 169 USPQ at 367 ¶3). Similarly, it is unclear based on the combination of the instant specification, and Gilles in WO 23/122320, whether the instantly recited substituted dimers of the Formula IG, wherein the substituted dimers of the Formula IG are not as presented herein in the section above entitled Claim Objections, are enabled. Likewise, the following excerpt is taken from Dörwald, which has relevance to the synthesis of substituted dimers of the Formula IG, wherein the substituted dimers of the Formula IG are not as presented herein in the section above entitled Claim Objections (Dörwald, F. Zaragoza. Side Reactions in Organic Synthesis: A Guide to Successful Synthesis Design, Weinheim: WILEY-VCH Verlag GmbH & Co. KGaA, 2005, Preface): Most non-chemists would probably be horrified if they were to learn how many attempted syntheses fail, and how inefficient research chemists are. The ratio of successful to unsuccessful chemical experiments in a normal research laboratory is far below unity, and synthetic research chemists, in the same way as most scientists, spend most of their time working out what went wrong, and why. Despite the many pitfalls lurking in organic synthesis, most organic chemistry textbooks and research articles do give the impression that organic reactions just proceed smoothly and that the total synthesis of complex natural products, for instance, is maybe a labor-intensive but otherwise undemanding task. In fact, most syntheses of structurally complex natural products are the result of several years of hard work by a team of chemists, with almost every step requiring careful optimization. The final synthesis usually looks quite different from that originally planned, because of unexpected difficulties encountered in the initially chosen synthetic sequence. Only the seasoned practitioner who has experienced for himself the many failures and frustrations which the development (sometimes even the repetition) of a synthesis usually implies will be able to appraise such work. Chemists tend not to publish negative results, because these are, as opposed to positive results, never definite (and far too copious). Next, the following excerpt is taken from Vippagunta, et al., with respect to the synthesis of solvates and/or hydrates of substituted dimers of the Formula IG (Vippagunta, et al. Advanced Drug Delivery Reviews, 48, 2001, 18): Predicting the formation of solvates or hydrates of a compound and the number of molecules of water or solvent incorporated into the crystal lattice of a compound is complex and difficult. Each solid compound responds uniquely to the possible formation of solvates or hydrates and hence generalizations cannot be made for a series of related compounds. Certain molecular shapes and features favor the formation of crystals without solvent; these compounds tend to be stabilized by efficient packing of molecules in the crystal lattice, whereas other crystal forms are more stable in the presence of water and/or solvents. There may be too many possibilities so that no computer programs are currently available for predicting the crystal structures of hydrates and solvates. Moreover, the following excerpt is taken from Burger’s, with respect to the synthesis of prodrugs of substituted dimers of the Formula IG (Wolff, Manfred E., Ed. Burger’s Medicinal Chemistry and Drug Discovery - Fifth Edition, Volume 1: Principles and Practice, New York: John Wiley & Sons, 1994, 975-977): The design of prodrugs in a rational manner requires that the underlying causes which necessitate or stimulate the use of the prodrug approach be defined and clearly understood. It may then be possible to identify the means by which the difficulties can be overcome. The rational design of the prodrug can thus be divided into three basic steps: (1) identification of the drug delivery problem; (2) identification of the physiochemical properties required for optimal delivery; and (3) selection of a prodrug derivative that has the proper physiochemical properties and that will be cleaved in the desired biological compartment. The difficulty of extrapolating data from animal to humans encountered during toxicokinetic and toxicologic studies with drugs is amplified with prodrugs, since not only metabolism of the active moiety might differ, but also its availability from the prodrug. As a matter of fact, there is presently no published rational for the conduct of animal and human pharmacokinetic programs during prodrug research and development. (f) Amount of direction provided by the inventor - the invention lacks direction with respect to making and/or using substituted dimers of the Formula IG, wherein the substituted dimers of the Formula IG are not as presented herein in the section above entitled Claim Objections; (g) Existence of working examples - the inventor or joint inventor has provided sufficient guidance to make and/or use substituted dimers of the Formula IG, wherein the substituted dimers of the Formula IG are as presented herein in the section above entitled Claim Objections; however, the disclosure is insufficient to allow extrapolation of the limited examples to enable the instantly recited substituted dimers of the Formula IG, wherein the substituted dimers of the Formula IG are not as presented herein in the section above entitled Claim Objections. The specification lacks working examples of substituted dimers of the Formula IG, wherein the substituted dimers of the Formula IG are not as presented herein in the section above entitled Claim Objections. Within the specification, [A]t least one specific operative embodiment or example of the invention must be set forth. The example(s) and description should be of sufficient scope as to justify the scope of the claims. Markush claims must be provided with support in the disclosure for each member of the Markush group. Where the constitution and formula of a chemical compound is stated only as a probability or speculation, the disclosure is not sufficient to support claims identifying the compound by such composition or formula. See MPEP § 608.01(p) and MPEP § 2173.05. PNG media_image5.png 125 319 media_image5.png Greyscale (h) Quantity of experimentation needed to make or use the invention based on the content of the disclosure - predicting whether a recited compound is in fact one that produces a desired physiological effect at a therapeutic concentration and with useful kinetics, is filled with experimental uncertainty, and without proper guidance, would involve a substantial amount of experimentation (Jordan, V. C. Nature Reviews: Drug Discovery, 2, 2003, 205-213). Similarly, the specification, as originally filed, including any references incorporated therein, fails to provide the necessary support required by 35 U.S.C. § 112(a) to enable the instantly recited substituted dimers of the Formula IG, wherein the substituted dimers of the Formula IG are not as presented herein in the section above entitled Claim Objections. Thus, it is unclear, based on the guidance provided by the specification, whether a hydrate of a substituted dimer of the Formula IG, such as 1,5-bis[3-[2-(dimethylamino)ethyl]-1H-indol-4-yl]-pentanedioic acid ester dihydrate, shown to the left above, is either synthetically feasible or possesses utility as a polypodal serotonergic. A conclusion of lack of enablement means that, based on the evidence regarding each of the above factors, the specification, at the time the invention was filed, would not have taught one skilled in the art how to make and/or use the full scope of the claimed invention without undue experimentation. {See In re Wright, 999 F.2d 1557, 1562, 27 USPQ2d 1510, 1513 (Fed. Cir. 1993)}. The determination that undue experimentation would have been needed to make and use the claimed invention is not a single, simple factual determination. Rather, it is a conclusion reached by weighing all the above noted factual considerations. (See In re Wands, 858 F.2d at 737, 8 USPQ2d at 1404). These factual considerations are discussed comprehensively in MPEP § 2164.08 (scope or breadth of the claims), § 2164.05(a) (nature of the invention and state of the prior art), § 2164.05(b) (level of one of ordinary skill), § 2164.03 (level of predictability in the art and amount of direction provided by the inventor or joint inventor), § 2164.02 (the existence of working examples) and § 2164.06 (quantity of experimentation needed to make or use the invention based on the content of the disclosure). Based on a preponderance of the evidence presented herein, the conclusion that the inventor or joint inventor is insufficiently enabled for making and/or using substituted dimers of the Formula IG, wherein the substituted dimers of the Formula IG are not as presented herein in the section above entitled Claim Objections, is clearly justified. The examiner suggests amending the claims, particularly as stated in the section above entitled Claim Objections, to overcome this rejection. Claim Rejections - 35 U.S.C. § 112(b) The following is a quotation of the second paragraph of 35 U.S.C. § 112: (b) CONCLUSION. The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or joint inventor regards as the invention. Claims 1-14, 19, 23, 24, 27, 28 and 31 are rejected under 35 U.S.C. § 112(b) as being indefinite for failing to set forth the subject matter which the inventor or joint inventor regards as the invention. The inventor or joint inventor should note that the phrase, optionally substituted, in claim 1, with regard to L3, R1, R2, R2a, R3, R3’, R3a, R3a’, R5, R6, R7, R8, R9, R10, X, X1, Y, and/or Y1, respectively, is a relative phrase which renders the claims indefinite. The phrase, optionally substituted, is not defined by the claim, the specification does not provide an adequate standard for ascertaining the requisite degree, and one of ordinary skill in the art would not be reasonably apprised of the metes and bounds of the invention. The specification, on page 10, defines the term, substituted, using a boiler plate list of functional groups, such as deuterium, aryl, etc.; however, neither the specification, nor the claim, explicitly limits the invention to any specifically disclosed or recited embodiments. Consequently, the substituted dimers of the Formula IG have been rendered indefinite by the use of the phrase, optionally substituted, with regard to L3, R1, R2, R2a, R3, R3’, R3a, R3a’, R5, R6, R7, R8, R9, R10, X, X1, Y, and/or Y1, respectively. Moreover, the inventor or joint inventor should further note that [C]laims which depend from indefinite claims are also indefinite. {See Ex parte Cordova, 10 USPQ 2d 1949, 1952 (PTO Bd. App. 1989)}. The examiner suggests amending the claims, particularly as stated in the section above entitled Claim Objections, to overcome this rejection. Allowable Subject Matter No claims are allowed. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to DOUGLAS M. WILLIS, whose telephone number is 571-270-5757. The examiner may normally be reached on Monday thru Thursday from 8:00-6:00 EST. The examiner is also available on alternate Fridays. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Mr. Jeffrey Murray, may be reached on 571-272-9023. The fax phone number for the organization where this invention or proceeding is assigned is 571-273-8300. Information regarding the status of an invention may be obtained from Patent Center. For more information about Patent Center, see https://www.uspto.gov/patents/apply/patent-center. Should you have questions on access to Patent Center, contact the Patent Electronic Business Center (PEBC) at 866-217-9197 (toll-free) or ebc@uspto.gov. /DOUGLAS M WILLIS/ Primary Examiner, Art Unit 1624
Read full office action

Prosecution Timeline

Jun 06, 2024
Application Filed
Sep 23, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12799136
THIOPHENE-PHENOTHIAZINE COMPOUNDS AND SYNTHESIS METHOD THEREOF, AS WELL AS APPLICATION THEREOF IN PREPARATION OF PHOTOTHERAPY MEDICINES
2y 7m to grant Granted Nov 17, 2026
Patent 12799124
METHOD FOR PREPARING TRIAZOLOPYRIMIDINONE DERIVATIVE
2y 5m to grant Granted Nov 17, 2026
Patent 12788697
TOPICAL AGENTS FOR DERMATOLOGICAL APPLICATIONS
4y 0m to grant Granted Nov 10, 2026
Patent 12778965
COMBINATION CANCER THERAPY WITH PENTAAZA MACROCYCLIC RING COMPLEX AND HORMONE THERAPY AGENT
3y 11m to grant Granted Nov 03, 2026
Patent 12780838
MTORC1 MODULATORS AND USES THEREOF
3y 8m to grant Granted Nov 03, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
82%
Grant Probability
99%
With Interview (+19.8%)
1y 10m (~0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1825 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month